Patient characteristics
| Characteristic . | Overall N = 1357 . | AML17 n = 888 . | AML19 n = 469 . |
|---|---|---|---|
| Median age (range), y | 53 (6-76) | 53 (6-76) | 53 (18-71) |
| Age ≥60 y | 267 (20%) | 200 (23%) | 67 (14%) |
| Female | 771 (57%) | 508 (57%) | 263 (56%) |
| Previous hematological disorder | 61 (4.5%) | 44 (5.0%) | 17 (3.6%) |
| Previous chemotherapy or radiotherapy | 24 (1.8%) | 16 (1.8%) | 8 (1.7%) |
| WCC (IQR) | 21 (7-55) | 22 (7-54) | 20 (6-57) |
| Hemoglobin (IQR) | 9.0 (7.7-10.3) | 9.1 (7.8-10.3) | 8.8 (7.7-10.5) |
| Platelets (IQR) | 64 (39-110) | 64 (38-10) | 66 (40-109) |
| BM blast, % (IQR) | 69 (41-86) | 70 (46-88) | 62 (38-81) |
| Cytogenetic risk group | |||
| Normal | 1168 (86%) | 771 (87%) | 397 (85%) |
| Intermediate | 130 (9.6%) | 78 (8.8%) | 52 (11%) |
| Adverse | 17 (1.3%) | 9 (1.0%) | 8 (1.7%) |
| Not available | 42 (3.1%) | 30 (3.4%) | 12 (2.6%) |
| NPM1mutation type | |||
| Type A | 1020 (75%) | 680 (77%) | 340 (72%) |
| Type B | 91 (6.7%) | 56 (6.3%) | 35 (7.5%) |
| Type D | 97 (7.1%) | 50 (5.6%) | 47 (10%) |
| Non-ABD | 149 (11%) | 102 (11%) | 47 (10%) |
| FLT3-ITD | 525 (39%) | 347 (39%) | 178 (38%) |
| Low allelic ratio | 298 (57%) | 181 (52%) | 117 (66%) |
| High allelic ratio | 225 (43%) | 166 (48%) | 59 (34%) |
| DNMT3A | 575 (52%) | 343 (51%) | 232 (54%) |
| Combined DNMT3A and FLT3-ITD | |||
| Neither mutated | 344 (31%) | 211 (32%) | 133 (31%) |
| Both mutated | 255 (23%) | 154 (23%) | 101 (23%) |
| DNMT3A only | 320 (29%) | 189 (28%) | 131 (30%) |
| FLT3-ITD only | 179 (16%) | 113 (17%) | 66 (15%) |
| FLT3-TKD | 206 (15%) | 123 (14%) | 83 (18%) |
| PTPN11 | 210 (19%) | 110 (16%) | 100 (23%) |
| NRAS | 194 (18%) | 113 (17%) | 81 (19%) |
| KRAS | 62 (5.6%) | 29 (4.3%) | 33 (7.7%) |
| TET2 | 179 (16%) | 121 (18%) | 58 (13%) |
| IDH2 | 174 (16%) | 101 (15%) | 73 (17%) |
| IDH1 | 151 (14%) | 81 (12%) | 70 (16%) |
| WT1 | 127 (12%) | 62 (9.3%) | 65 (15%) |
| RAD21 | 77 (7.0%) | 49 (7.3%) | 28 (6.5%) |
| MYC | 64 (5.8%) | 39 (5.8%) | 25 (5.8%) |
| CEBPA | 61 (5.6%) | 34 (5.1%) | 27 (6.3%) |
| MDS-associated mutations | 132 (12%) | 67 (10%) | 65 (15%) |
| SRSF2 | 56 (5.1%) | 27 (4.0%) | 29 (6.7%) |
| STAG2 | 40 (3.6%) | 23 (3.4%) | 17 (3.9%) |
| ASXL1 | 13 (1.2%) | 9 (1.3%) | 4 (0.9%) |
| BCOR | 5 (0.5%) | 2 (0.3%) | 3 (0.7%) |
| RUNX1 | 11 (1.0%) | 5 (0.7%) | 6 (1.4%) |
| SF3B1 | 10 (0.9%) | 4 (0.6%) | 6 (1.4%) |
| EZH2 | 9 (0.8%) | 4 (0.6%) | 5 (1.2%) |
| U2AF1 | 5 (0.5%) | 3 (0.4%) | 2 (0.5%) |
| ZRSR2 | 1 (<0.1%) | 1 (0.1%) | 0 (0%) |
| SMC3 | 54 (4.9%) | 33 (4.9%) | 21 (4.9%) |
| GATA2 | 44 (4.0%) | 21 (3.1%) | 23 (5.3%) |
| SMC1A | 44 (4.0%) | 26 (3.9%) | 18 (4.2%) |
| NF1 | 43 (3.9%) | 24 (3.6%) | 19 (4.4%) |
| TP53 | 16 (1.5%) | 3 (0.4%) | 13 (3.0%) |
| Induction chemotherapy | |||
| Other (DA/ADE/CPX-351) | 1125 (83%) | 888 (100%) | 237 (51%) |
| FLAG-Ida | 232 (17%) | 0 (0%) | 232 (49%) |
| Gemtuzumab with induction | 526 (39%) | 216 (24%) | 310 (66%) |
| Allogeneic transplant | |||
| Transplant in CR1 | 304 (22%) | 179 (20%) | 125 (27%) |
| Transplant at other stages | 235 (17%) | 170 (19%) | 65 (14%) |
| No transplant | 818 (60%) | 539 (61%) | 279 (59%) |
| Characteristic . | Overall N = 1357 . | AML17 n = 888 . | AML19 n = 469 . |
|---|---|---|---|
| Median age (range), y | 53 (6-76) | 53 (6-76) | 53 (18-71) |
| Age ≥60 y | 267 (20%) | 200 (23%) | 67 (14%) |
| Female | 771 (57%) | 508 (57%) | 263 (56%) |
| Previous hematological disorder | 61 (4.5%) | 44 (5.0%) | 17 (3.6%) |
| Previous chemotherapy or radiotherapy | 24 (1.8%) | 16 (1.8%) | 8 (1.7%) |
| WCC (IQR) | 21 (7-55) | 22 (7-54) | 20 (6-57) |
| Hemoglobin (IQR) | 9.0 (7.7-10.3) | 9.1 (7.8-10.3) | 8.8 (7.7-10.5) |
| Platelets (IQR) | 64 (39-110) | 64 (38-10) | 66 (40-109) |
| BM blast, % (IQR) | 69 (41-86) | 70 (46-88) | 62 (38-81) |
| Cytogenetic risk group | |||
| Normal | 1168 (86%) | 771 (87%) | 397 (85%) |
| Intermediate | 130 (9.6%) | 78 (8.8%) | 52 (11%) |
| Adverse | 17 (1.3%) | 9 (1.0%) | 8 (1.7%) |
| Not available | 42 (3.1%) | 30 (3.4%) | 12 (2.6%) |
| NPM1mutation type | |||
| Type A | 1020 (75%) | 680 (77%) | 340 (72%) |
| Type B | 91 (6.7%) | 56 (6.3%) | 35 (7.5%) |
| Type D | 97 (7.1%) | 50 (5.6%) | 47 (10%) |
| Non-ABD | 149 (11%) | 102 (11%) | 47 (10%) |
| FLT3-ITD | 525 (39%) | 347 (39%) | 178 (38%) |
| Low allelic ratio | 298 (57%) | 181 (52%) | 117 (66%) |
| High allelic ratio | 225 (43%) | 166 (48%) | 59 (34%) |
| DNMT3A | 575 (52%) | 343 (51%) | 232 (54%) |
| Combined DNMT3A and FLT3-ITD | |||
| Neither mutated | 344 (31%) | 211 (32%) | 133 (31%) |
| Both mutated | 255 (23%) | 154 (23%) | 101 (23%) |
| DNMT3A only | 320 (29%) | 189 (28%) | 131 (30%) |
| FLT3-ITD only | 179 (16%) | 113 (17%) | 66 (15%) |
| FLT3-TKD | 206 (15%) | 123 (14%) | 83 (18%) |
| PTPN11 | 210 (19%) | 110 (16%) | 100 (23%) |
| NRAS | 194 (18%) | 113 (17%) | 81 (19%) |
| KRAS | 62 (5.6%) | 29 (4.3%) | 33 (7.7%) |
| TET2 | 179 (16%) | 121 (18%) | 58 (13%) |
| IDH2 | 174 (16%) | 101 (15%) | 73 (17%) |
| IDH1 | 151 (14%) | 81 (12%) | 70 (16%) |
| WT1 | 127 (12%) | 62 (9.3%) | 65 (15%) |
| RAD21 | 77 (7.0%) | 49 (7.3%) | 28 (6.5%) |
| MYC | 64 (5.8%) | 39 (5.8%) | 25 (5.8%) |
| CEBPA | 61 (5.6%) | 34 (5.1%) | 27 (6.3%) |
| MDS-associated mutations | 132 (12%) | 67 (10%) | 65 (15%) |
| SRSF2 | 56 (5.1%) | 27 (4.0%) | 29 (6.7%) |
| STAG2 | 40 (3.6%) | 23 (3.4%) | 17 (3.9%) |
| ASXL1 | 13 (1.2%) | 9 (1.3%) | 4 (0.9%) |
| BCOR | 5 (0.5%) | 2 (0.3%) | 3 (0.7%) |
| RUNX1 | 11 (1.0%) | 5 (0.7%) | 6 (1.4%) |
| SF3B1 | 10 (0.9%) | 4 (0.6%) | 6 (1.4%) |
| EZH2 | 9 (0.8%) | 4 (0.6%) | 5 (1.2%) |
| U2AF1 | 5 (0.5%) | 3 (0.4%) | 2 (0.5%) |
| ZRSR2 | 1 (<0.1%) | 1 (0.1%) | 0 (0%) |
| SMC3 | 54 (4.9%) | 33 (4.9%) | 21 (4.9%) |
| GATA2 | 44 (4.0%) | 21 (3.1%) | 23 (5.3%) |
| SMC1A | 44 (4.0%) | 26 (3.9%) | 18 (4.2%) |
| NF1 | 43 (3.9%) | 24 (3.6%) | 19 (4.4%) |
| TP53 | 16 (1.5%) | 3 (0.4%) | 13 (3.0%) |
| Induction chemotherapy | |||
| Other (DA/ADE/CPX-351) | 1125 (83%) | 888 (100%) | 237 (51%) |
| FLAG-Ida | 232 (17%) | 0 (0%) | 232 (49%) |
| Gemtuzumab with induction | 526 (39%) | 216 (24%) | 310 (66%) |
| Allogeneic transplant | |||
| Transplant in CR1 | 304 (22%) | 179 (20%) | 125 (27%) |
| Transplant at other stages | 235 (17%) | 170 (19%) | 65 (14%) |
| No transplant | 818 (60%) | 539 (61%) | 279 (59%) |
ADE, cytarabine, daunorubicin, etoposide; DA, daunorubicin, cytarabine; FLAG-Ida, fludarabine, cytarabine, granulocyte colony-stimulating factor (G-CSF), idarubucin.